FibroGen, Inc (NASDAQ:FGEN) – Research analysts at Jefferies Group cut their Q3 2017 earnings estimates for shares of FibroGen in a note issued to investors on Monday. Jefferies Group analyst M. Yee now anticipates that the biopharmaceutical company will earn ($0.49) per share for the quarter, down from their prior estimate of ($0.42). Jefferies Group currently has a “Buy” rating and a $75.00 target price on the stock. Jefferies Group also issued estimates for FibroGen’s Q4 2017 earnings at ($0.49) EPS, FY2017 earnings at ($1.98) EPS and FY2018 earnings at ($0.91) EPS.

FGEN has been the topic of a number of other reports. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a report on Friday, July 21st. BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a report on Monday, May 8th. Citigroup Inc. restated a “buy” rating and set a $48.00 target price on shares of FibroGen in a report on Monday, June 26th. Finally, Stifel Nicolaus boosted their target price on shares of FibroGen from $38.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $60.17.

WARNING: “Q3 2017 Earnings Estimate for FibroGen, Inc (FGEN) Issued By Jefferies Group” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/q3-2017-earnings-estimate-for-fibrogen-inc-fgen-issued-by-jefferies-group/1467277.html.

Shares of FibroGen (NASDAQ FGEN) opened at 43.65 on Thursday. The company’s market capitalization is $3.05 billion. FibroGen has a 12-month low of $15.60 and a 12-month high of $51.70. The company’s 50 day moving average is $34.38 and its 200 day moving average is $28.07.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.01. The business had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%.

In related news, CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $26.21, for a total transaction of $1,012,649.56. Following the transaction, the chief executive officer now directly owns 3,345,941 shares in the company, valued at $87,697,113.61. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Pat Cotroneo sold 2,891 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $28.75, for a total transaction of $83,116.25. Following the transaction, the vice president now owns 163,366 shares in the company, valued at $4,696,772.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 404,974 shares of company stock worth $12,515,438. 14.90% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in FibroGen by 29,724.1% in the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after buying an additional 4,439,882 shares during the period. Norges Bank bought a new position in FibroGen during the fourth quarter worth approximately $8,480,000. Vanguard Group Inc. boosted its position in FibroGen by 8.4% in the first quarter. Vanguard Group Inc. now owns 5,047,018 shares of the biopharmaceutical company’s stock worth $124,409,000 after buying an additional 392,778 shares during the period. Bogle Investment Management L P DE boosted its position in FibroGen by 215.8% in the first quarter. Bogle Investment Management L P DE now owns 329,371 shares of the biopharmaceutical company’s stock worth $8,118,000 after buying an additional 225,083 shares during the period. Finally, Prudential Financial Inc. boosted its position in FibroGen by 95.2% in the first quarter. Prudential Financial Inc. now owns 409,350 shares of the biopharmaceutical company’s stock worth $10,090,000 after buying an additional 199,670 shares during the period. Institutional investors and hedge funds own 43.45% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.